Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer

Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer

IntroductionProgrammed death-ligand 1 (PD-L1) blockade is a growing treatment for extensive-stage small cell lung cancer (ES-SCLC). This study evaluates the cost-effectiveness of benmelstobart and anlotinib plus etoposide/carboplatin (EC) compared versus anlotinib plus EC and EC alone for patients w...

Full description

Saved in:
Bibliographic Details
Main Authors: Jing Nie, Conghui Kou, Ke Tang, Siyu Dai, Xifeng Zhao, Jiyong Wu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Pharmacology
Subjects:
extensive-stage small-cell lung cancer
benmelstobart
anlotinib
carboplatin
etoposide
cost-effectiveness
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1524108/full

Similar Items